BR112022002094A2 - Composição imunogênica - Google Patents

Composição imunogênica

Info

Publication number
BR112022002094A2
BR112022002094A2 BR112022002094A BR112022002094A BR112022002094A2 BR 112022002094 A2 BR112022002094 A2 BR 112022002094A2 BR 112022002094 A BR112022002094 A BR 112022002094A BR 112022002094 A BR112022002094 A BR 112022002094A BR 112022002094 A2 BR112022002094 A2 BR 112022002094A2
Authority
BR
Brazil
Prior art keywords
immunogenic composition
staphylococcus
antigens
prevention
treatment
Prior art date
Application number
BR112022002094A
Other languages
English (en)
Inventor
Daniela Stranges
Giovanna Campanella
Simone Bufali
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112022002094A2 publication Critical patent/BR112022002094A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composição imunogênica.a presente invenção refere-se a uma composição imunogênica que compreende antígenos de staphylococcus, contendo antígenos de proteínas e conjugados de polissacarídeos capsulares. também são providas formulações com adjuvante. a invenção pode encontrar uso na prevenção e no tratamento de infecções causadas por staphylococcus.
BR112022002094A 2019-08-15 2020-08-10 Composição imunogênica BR112022002094A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19191991.9A EP3777884A1 (en) 2019-08-15 2019-08-15 Immunogenic composition
PCT/EP2020/072428 WO2021028402A1 (en) 2019-08-15 2020-08-10 Immunogenic composition

Publications (1)

Publication Number Publication Date
BR112022002094A2 true BR112022002094A2 (pt) 2022-04-19

Family

ID=67659013

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002094A BR112022002094A2 (pt) 2019-08-15 2020-08-10 Composição imunogênica

Country Status (8)

Country Link
US (1) US20220395566A1 (pt)
EP (2) EP3777884A1 (pt)
JP (1) JP2022544407A (pt)
CN (1) CN114585381A (pt)
BR (1) BR112022002094A2 (pt)
CA (1) CA3150545A1 (pt)
MX (1) MX2022001937A (pt)
WO (1) WO2021028402A1 (pt)

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
WO1988009797A1 (en) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Autocrine motility factors in cancer diagnosis and management
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
KR950700081A (ko) 1992-02-11 1995-01-16 W 로우 죤 이중 캐리어 면역원성 구성물
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
DE69428136T3 (de) 1993-03-23 2008-07-10 Smithkline Beecham Biologicals S.A. 3-0-Deazylierte Monophosphoryl Lipid A enthaltende Impfstoff-Zusammensetzungen
EP0720485B1 (en) 1993-09-22 2003-11-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
AU712981B2 (en) 1995-03-22 1999-11-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
AU2003205502C1 (en) 2002-03-07 2011-08-25 Eidgenossische Technische Hochschule Zurich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
SI2311972T1 (sl) 2005-05-11 2015-08-31 Eth Zuerich Rekombinantni N-glikozilirani proteini iz prokariontskih celic
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CN101983070B (zh) 2008-02-20 2016-03-30 格林考瓦因有限公司 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Preparations and method for Protein A (SPA) variants
SG176837A1 (en) * 2009-06-22 2012-01-30 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
US9353160B2 (en) 2009-07-16 2016-05-31 Glaxosmithkline Biologicals S.A. Method of prophlactically treating infection using a recombinant fibrinogen binding protein clumping factor A (ClfA) or fragment thereof
AU2010273142B2 (en) 2009-07-17 2013-10-17 Ocean Harvest Technology (Canada) Inc. Natural and sustainable seaweed formula that replaces synthetic additives in fish feed
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
DK2566507T3 (da) 2010-05-06 2018-01-29 Glaxosmithkline Biologicals Sa Biokonjugatvacciner med kapselformige grampositive bakterier
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
EP2480253B1 (en) 2010-09-01 2014-01-22 Novartis AG Adsorption of immunopotentiators to insoluble metal salts
US9730992B2 (en) 2010-12-14 2017-08-15 Glaxosmithkline Biologicals S.A. Mycobacterium antigenic composition
BR112015004817A2 (pt) 2012-09-10 2017-07-04 Glycovaxyn Ag bioconjugados compreendendo antígenos modificados e seus usos
EA037818B1 (ru) 2014-03-26 2021-05-25 Глаксосмитклайн Байолоджикалс С.А. Мутантные стафилококковые антигены
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus
EP3240895B1 (en) 2014-12-30 2022-01-26 GlaxoSmithKline Biologicals S.A. Compositions and methods for protein glycosylation
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition

Also Published As

Publication number Publication date
WO2021028402A1 (en) 2021-02-18
EP4013449A1 (en) 2022-06-22
US20220395566A1 (en) 2022-12-15
MX2022001937A (es) 2022-03-11
CA3150545A1 (en) 2021-02-18
EP3777884A1 (en) 2021-02-17
CN114585381A (zh) 2022-06-03
JP2022544407A (ja) 2022-10-18

Similar Documents

Publication Publication Date Title
MX2021015775A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos.
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
BR112018007525A2 (pt) composições imunogênicas de circovírus suíno tipo 3 e métodos de produzir e usar as mesmas
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
RU2017123262A (ru) Иммуногенные композиции для применения в пневмококковых вакцинах
CO6260103A2 (es) Composiciones que comprenden antigenos neumococidos
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
EA201691478A1 (ru) Новый полисахарид и его применения
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
AR059688A1 (es) Uso de alfa - toxina para tratar y prevenir las infecciones por staphylococcus
PE20190458A1 (es) Composiciones de neisseria meningitidis y metodos de las mismas
CR10555A (es) Vacunas para malaria
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
TW200633719A (en) Glycoconjugate vaccines containing peptidoglycan
MA32388B1 (fr) Immunomodulation par des inhibiteurs d'iap
MX2022015734A (es) Proteinas de exotoxina a modificadas.
ZA202310611B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2020009935A (es) Formulaciones acuosas y estables de anticuerpos anti-tau.
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
BR112017015288A2 (pt) vacina contra febre aftosa
WO2022249107A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MA45283B1 (fr) Une composition de multivalent pneumococcal la protéine de polysaccaride-transporteur capsulaire se conjugue et utilisez de cela

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]